clinically demonstrated Articles
-
Lehigh Valley Health Network: External Beam Electron Treatment with 3D Printed Modulated and Simple Bolus - Case Study
This patient case demonstrates the clinical application of Adaptiiv’s technology used in radiation oncology through the design and fabrication of both modulated and uniform thickness (simple) ...
-
Clinical CRISPR Success Demonstrates Need for Quality Control
The Clinical CRISPR Successes Are Stacking Up. But Where’s the Emphasis on Quality Control? In mid-September, Intellia released some promising data on two of their CRISPR-based therapeutics. These results are a significant milestone for genome editing and validation of its effectiveness in the clinic. However, the safety of CRISPR-based therapeutics has been a major concern and part of a ...
By CRISPR QC
-
Change in Number of Shares and Votes in Bonesupport Holding Ab (PUBL)
BONESUPPORT Holding AB (publ), an emerging leader in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. During August, the number of shares and votes in BONESUPPORT Holding AB (publ) has increased with 10,000 due to the exercise of warrants. As of 31 August 2021, the number of shares in BONESUPPORT HOLDING AB (publ) amounts to ...
-
Multidrug resistance in fungi
One of the major advances serving to define the beginning of the era of modern medicine was the development of penicillin in the early 1940s as the first widely used antibiotic effective against microorganisms (reviewed in reference 111). In what has become an all-too-common trend, antibiotic-resistant isolates emerged soon after the large-scale use of penicillin to treat bacterial infections ...
-
Multidrug resistance in fungi
One of the major advances serving to define the beginning of the era of modern medicine was the development of penicillin in the early 1940s as the first widely used antibiotic effective against microorganisms (reviewed in reference 111). In what has become an all-too-common trend, antibiotic-resistant isolates emerged soon after the large-scale use of penicillin to treat bacterial infections ...
-
A Bayesian design for phase I cancer therapeutic vaccine trials
Abstract Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not ...
-
Exploring Knowledge Graphs for COVID-19 Drug Discovery
Today, there are only a few therapies approved to treat COVID-19, but while novel therapies can take decades and billions of dollars to develop, are there opportunities to repurpose existing drugs for new therapies? Our latest whitepaper showcases how CAS Knowledge Graphs reveal new connections and insights that identify drugs to potentially repurpose. Drug repurposing is critical for faster ...
-
Study Results On Fortify Are Inconclusive
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced inconclusive results for the company’s Investigational Device Exemption (IDE) study; FORTIFY. The primary safety endpoint for CERAMENT G was met. The FORTIFY study was initiated in 2017 with the purpose to evaluate the ability of CERAMENT G to improve the treatment outcomes for ...
-
A Revolution of EVAR Imaging Technologies
Endovascular aneurysm repair (EVAR) has dramatically evolved over the past 2 decades—from relatively simple tubular endografts to extraordinarily complex branched endografts that allow endovascular coverage from the sinotubular junction through the iliac bifurcation. With this increasing complexity of repairs, parallel improvements in imaging and navigation technologies have ensued. These ...
-
Gene.iobio Paper Published in Nature Scientific Reports
We are proud to announce that the gene.iobio paper has been published in Nature Scientific Reports. This tool has been developed at the University of Utah, with significant contribution from Frameshift co-founders. As genomic data is increasingly being used to aid in disease diagnostics, there is a growing need for easy-to-use tools to enable diagnosticians to interpret complex or uncertain ...
-
Early Experience with a Novel Hemodialysis System used for PIRRT Demonstrates Clinical Management at Lower Cost than CRRT and IHD - Case Study
The need for providing dialysis to patients in the ICU has increased overtime. Delivery of this care is challenging to health care systems (HCS) both in costs and ...
-
Understanding the Benefits of Probiotic Formula for Gut Health
The gut microbiota, a diverse community of microorganisms residing in our gastrointestinal tract, plays a crucial role in maintaining our overall health. Probiotics, live microorganisms with potential health benefits, have garnered significant attention for their ability to promote gut health. In this article, we will delve into the science behind probiotic formulas, exploring their mechanisms of ...
-
Breakthrough Device Designation Received From the FDA for EndoArt
NESS ZIONA, Israel, Feb. 5, 2020 /PRNewswire/ -- EyeYon Medical (https://eye-yon.com/) is a start-up company developing a variety of ophthalmic products for vision-threatening conditions. EyeYon's new product, now on an accelerated path as a Breakthrough Device, is an Artificial Endothelial Layer - EndoArt® - a polymer film implant, attached to the posterior corneal surface, to treat chronic ...
-
Ischemic Stroke: The First Pass Effect
It's been less than five years since, beginning with MR CLEAN, a series of landmark trials validated the role of clot-removing (thrombectomy) devices that can open up large vessel occlusions in the anterior circulation of patients experiencing acute ischemic stroke. But the field is moving fast. Mechanical thrombectomy devices known as stent retrievers (or stentrievers) and aspiration catheters ...
-
Arterial reconstruction with human bioengineered acellular blood vessels in patients with peripheral arterial disease
Abstract Objective: Vascular conduit is essential for arterial reconstruction for a number of conditions, including trauma and atherosclerotic occlusive disease. We have developed a tissue-engineered human acellular vessel (HAV) that can be manufactured, stored on site at hospitals, and be immediately available for arterial vascular reconstruction. Although the HAV is acellular when implanted, ...
-
Reconstruction of tissues affected by Pilonidal Sinus Disease
Highlights • AROA’s Myriad Matrix™ is further validated in a clinical study and peer-reviewed publication in Journal of Wound Care. • Study of six patients shows 100% success rates from use of Myriad Matrix™ as an implant during surgical reconstruction of soft tissues affected by Pilonidal Sinus Disease (PSD). • All patients healed well with no major complications ...
-
Abstract 4842: A comparative preclinical study of PARP inhibitors demonstrates superb properties for IDX-1197
Abstract Background PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. We aimed to develop a novel PARP inhibitor that may have potent antitumor efficacy. IDX-1197 is a novel, potent, selective, and orally bioavailable poly (ADP-ribose) ...
-
AstaPure® EyeQ: Natural astaxanthin for Eyes and brain - Download the eBook!
Inspired by the superb vision and natural mechanism of the eagle's eye, Algatechnologies introduces AstaPure® EyeQ. a clinically supported, microencapsulated, cold water-soluble 2% natural astaxanthin powder. AstaPure® EyeQ is a highly pure extract derived from Haematococcus pluvialis microalgaer a species of microalgae known to be the richest source of natural astaxanthin. As a ...
By Algatech
-
Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor
Abstract Background: PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. However, there still needs more improvement in efficacy because PARP inhibitors have comparatively low efficacy in non-germline BRCA-mutated patients. We aimed to develop ...
-
Science: Knockout of this epigenetic gene gives CAR-T cells the ability to continuously attack cancer cells
Simply put, CAR-T is to transform the patient's immune T cells in vitro by biotechnology, so that they recognize antigens on the surface of tumor cells, and then inject these cells back into the patient to achieve the therapeutic effect of recognizing and killing cancer cells. In 2017, CAR-T therapy was first approved by the FDA for the treatment of blood cancers such as leukemia and lymphoma. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you